Cyclacel Pharmaceuticals (CYCC) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing cancer medicines targeting cell cycle, epigenetics, and mitosis biology.

• Lead program is plogosertib (PLK1 inhibitor) in Phase 1/2 trials for solid tumors and hematological malignancies.

• Recent strategic shift to focus solely on plogosertib after liquidating UK subsidiary and discontinuing other programs.

• Business model includes selective partnerships for commercialization and leveraging intellectual property.

Financial performance and metrics

• Cash and cash equivalents as of December 31, 2024, were $3.1 million; private placement proceeds of $4.1 million in Q1 2025.

• Accumulated deficit of $439.5 million as of December 31, 2024; net loss of $11.2 million for 2024.

• Company anticipates liquidity only into Q2 2025 without additional funding.

• Deconsolidation of UK subsidiary expected to increase stockholders' equity by $5.0 million.

Use of proceeds and capital allocation

• No proceeds will be received from the sale of shares by selling shareholders; all proceeds go to selling shareholders.

• Recent private placements used for general corporate and operating purposes, including settling liabilities.